ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Five of nine analysts recommend buying ANI Pharmaceuticals, while four rate it a hold. The average 12-month price target is $105.57.
• Quarterly results exceeded expectations: ANI reported earnings of $2.21 per share versus the $2.04 consensus estimate, while revenue rose 25.8% year over year to $266.04 million.
• Shares remain near their one-year low: ANIP opened at $70.19, compared with a 52-week range of $69.58 to $99.39. Insiders sold 21,425 shares worth $1.69 million over the past 90 days, while institutional investors own 76.05% of the stock.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $105.5714.

Several research firms recently weighed in on ANIP. Weiss Ratings downgraded ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Guggenheim dropped their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday. They issued an "outperform" rating and a $104.00 target price on the stock. Finally, Canaccord Genuity Group reduced their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th.

Insider Activity

In other ANI Pharmaceuticals news, CFO Stephen Carey sold 2,850 shares of the firm's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $72.80, for a total transaction of $207,480.00. Following the completion of the sale, the chief financial officer directly owned 171,843 shares in the company, valued at approximately $12,510,170.40. This trade represents a 1.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares of the company's stock, valued at $5,617,523.52. This trade represents a 0.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 21,425 shares of company stock valued at $1,687,370. Company insiders own 8.10% of the company's stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company's stock worth $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at $48,000. Finally, State of Wyoming bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $50,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ ANIP opened at $70.19 on Friday. ANI Pharmaceuticals has a 1 year low of $69.58 and a 1 year high of $99.39. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a 50-day moving average of $77.26 and a 200 day moving average of $78.19. The stock has a market cap of $1.61 billion, a P/E ratio of 15.13 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to analysts' expectations of $260.13 million. During the same quarter in the prior year, the company earned $1.80 earnings per share. The business's revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts expect that ANI Pharmaceuticals will post 7.83 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.